State Street Corp Acquires 148,414 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX)

State Street Corp lifted its stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 24.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 756,499 shares of the company’s stock after buying an additional 148,414 shares during the period. State Street Corp’s holdings in TScan Therapeutics were worth $3,767,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP acquired a new position in TScan Therapeutics in the 2nd quarter valued at $70,000. SG Americas Securities LLC bought a new position in shares of TScan Therapeutics in the third quarter worth $78,000. The Manufacturers Life Insurance Company acquired a new position in TScan Therapeutics in the second quarter valued at about $90,000. MetLife Investment Management LLC lifted its position in TScan Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after purchasing an additional 13,164 shares during the period. Finally, Cornercap Investment Counsel Inc. acquired a new stake in TScan Therapeutics during the second quarter worth about $134,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Trading Down 2.0 %

TCRX opened at $3.00 on Tuesday. The company has a market cap of $160.11 million, a P/E ratio of -2.83 and a beta of 0.79. TScan Therapeutics, Inc. has a 1-year low of $2.60 and a 1-year high of $9.69. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $4.32 and its 200-day moving average is $5.44.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.86 million. Equities research analysts predict that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TCRX. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Monday, December 23rd.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.